+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07771855

Evaluating Tezepelumab for Managing Chronic Bronchial Disease After Allogeneic Stem Cell Transplantation in Adults

Led by Hopital Foch · Updated on 2026-08-18

36

Participants Needed

6

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the use of an anti-TSLP monoclonal antibody called tezepelumab to manage chronic bronchial disease caused by bronchiolitis obliterans syndrome BOS in adults who have received allogeneic hematopoietic stem cell transplants HSCT. BOS is a severe lung condition that can develop after transplant and is related to immune system complications, causing obstructive lung problems and repeated bronchial exacerbations. This phase 2 study aims to evaluate if tezepelumab can reduce bronchial exacerbations in patients whose lung disease is not actively linked to graft versus host disease GVHD. Participants will receive tezepelumab through subcutaneous injections of 210 mg once every four weeks over 12 months, totaling 13 injections. The first injection and injections at specific visits will be given at the study center, while others will be administered at the participants home by a nurse. This approach follows the recent advances in targeted biotherapies that reduce inflammation and corticosteroid use in severe bronchial diseases. During the study, participants will be closely monitored through various lung function tests, questionnaires assessing asthma control and quality of life, and blood and sputum tests measuring inflammation markers. Researchers will measure the change in the number of bronchial exacerbations over 13 months as the primary outcome. Other outcomes include hospitalizations, corticosteroid use, lung capacity measures, and quality of life scores. The study includes safety monitoring and regular follow-up visits throughout the treatment period.

CONDITIONS

Brief Title

Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients

Research Team

Y

Yahya DEBZA

D

DRCI Promotion

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here